
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative medicines called Bicycles, which are synthetic short peptides that can be used to target a variety of diseases. The company's initial focus is on oncology, with its lead product candidate, BT1718, showing promising results as a Bicycle Toxin Conjugate in clinical trials. Despite recent setbacks in its development plans, the company's strong financials and partnerships in the UK and US make it a promising investment opportunity.
Bears say
Bicycle Therapeutics is facing several challenges that contribute to a negative outlook, including potential difficulties in their ongoing Ph 3 trial design discussions with regulatory authorities and uncertainties surrounding the appropriate comparator arm for the trial. Additionally, the company's reliance on their lead product candidate, BT1718, and their focus on oncology indications with high unmet medical needs may lead to clinical and regulatory risk. There is also a potential for competition from larger biopharmaceutical companies with similar capabilities and next-generation Nectin-4 ADCs that could limit Bicycle Therapeutics' market share and pricing power.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares